Evidence map›Paper›PMID 29486233›Full record

ArticleInternational journal of antimicrobial agents2018

Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.

Zackery P Bulman, Miao Zhao, Michael J Satlin, Liang Chen, Barry N Kreiswirth, Thomas J Walsh, Roger L Nation, Jian Li, Brian T Tsuji

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of antimicrobial agents, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Zackery P BulmanCollege of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: bulman@uic.edu.
Miao ZhaoInstitute of Antibiotics, Huashan Hospital, Fudan University & Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.
Michael J SatlinWeill Cornell Medical College, Cornell University, New York, NY, USA.
Liang ChenPublic Health Research Institute, New Jersey Medical School-Rutgers, The State University of New Jersey, Newark, NJ, USA.
Barry N KreiswirthPublic Health Research Institute, New Jersey Medical School-Rutgers, The State University of New Jersey, Newark, NJ, USA.
Thomas J WalshWeill Cornell Medical College, Cornell University, New York, NY, USA.
Roger L NationDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
Jian LiDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
Brian T TsujiSchool of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA. Electronic address: btsuji@buffalo.edu.
Cornell University · USMonash University · AURutgers, The State University of New Jersey · USFudan University · CNUniversity at Buffalo, State University of New York · USUniversity of Illinois Chicago · US

Funding

Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative SuperbugsR01AI111990 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LI, JIAN, TSUJI, BRIAN · 2014 to 2018
$4.4M
NIAID NIH HHS R01 AI111990
6 · The paper itself

Abstract

Polymyxin B (PMB) and fosfomycin are two 'old' antibiotics that consistently maintain activity against Klebsiella pneumoniae carbapenemase (KPC)-producing organisms based on in vitro susceptibility testing. However, the use of each antibiotic in monotherapy has been associated with high rates of treatment failure. Therefore, the objective of this study was to investigate the combinatorial pharmacodynamics of PMB and fosfomycin against KPC-producing K. pneumoniae (KPC-Kp). PMB front-loading (3.33 mg/kg for one dose, followed by 1.43 mg/kg every 12 h starting 12 h later) and burst (5.53 mg/kg for one dose, with no subsequent doses) simulated dosing regimens were explored in combination with fosfomycin (4 g every 8 h) against KPC-2-producing K. pneumoniae ST258 in a hollow-fibre infection model over 120 h. Population analysis profiles were used to track the temporal PMB and fosfomycin resistance profiles. Against isolate KPC-Kp 9A (PMB MIC = 0.5 mg/L; fosfomycin MIC ≤ 8 mg/L), monotherapies resulted in >3 log

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesDrug Resistance, Multiple, BacterialDrug Therapy, CombinationFosfomycinHumansKlebsiella InfectionsKlebsiella pneumoniaeMicrobial Sensitivity TestsPolymyxin BAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasescarbapenemasecarbapenemase-2, Klebsiella pneumoniaeFosfomycinPolymyxin BCarbapenemaseFosfomycinKPC-producing Klebsiella pneumoniaePharmacokinetics/pharmacodynamicsPolymyxin B

Identifiers

PMID29486233
PMCPMC6938411
OpenAlexW2790923801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.